Pattern of antibody response after either BNT162b2 or ChAdOx1 nCoV-19 as a booster shot following two shots of Sinovac-CoronaVac among healthcare workers
Keywords:
SARS-CoV-2, Sinovac, vaccine, BNT162b2, ChAdOx1 nCoV-19, immunogenicity, third dose, booster dose, healthcare worker, Anti-SARS-CoV-2 spike RBD antibodiesAbstract
Background: Two shots of Sinovac-Coronavac vaccine were provided to healthcare workers in Thailand during the early outbreak of SARS-CoV-2 infection. BNT162b2 or ChAdOx1 nCoV-19 has been used as a booster dose. However, at the time of this study conducted data of immunogenic response after boosting with BNT162b2 or ChAdOx1 nCoV-19 is limited.
Methods: The objective of our study was to measure the antibody response at one month after receiving BNT162b2(Pfizer-BioNTech) or ChAdOx1 nCoV-19(AstraZeneca) as the booster dose in healthcare worker who had fully vaccinated with two doses of Sinovac during August 2021 to 2022. Exclusion criteria were; diabetes mellitus, chronic kidney disease, immunodeficiency syndrome, cancer, BMI more than 35 kg per m2, BW more than 100 kg, pregnancy, lactation, postpartum, history of SARS-CoV-2 infection and currently taking immunosuppressive agent or prednisolone at least 20 mg per day within one month before receiving the third dose of vaccine. All participants’ blood samples were drawn at one month after the booster dose. Anti SARS- CoV-2 spike RBD antibodies were measured by Elecsys® Anti-SARS-CoV-2 S version 2 (ECLIA, Roche), an immunoassay.
Results: A total of 168 participants were enrolled, 86 received ChAdOx1 nCoV-19 and 82 received BNT162b2. Mean and median of anti SARS-CoV-2 spike RBD level in BNT162b2 group was 17,085.76 U/mL(10,723.3) and 15,104.69 U/mL(IQR 11,597.86) respectively, whereas mean and median of anti SARS-CoV-2 spike RBD level in ChAdOx1 nCoV-19 group was 4,677.01 U/mL(4,081.54) and 4,266.24 U/mL(IQR 5,875.59) respectively. Anti SARS-CoV-2 spike RBD antibodies level at one month after the booster vaccine was significantly higher in participants who received BNT162b2, mean difference 12,408.74(95% CI;9,958.70-14,858.78, p<0.001). Participants in neither BNT162b2 group nor ChAdOx1 nCoV-19 group has serious adverse event and incidence of SARS-CoV-2 infection within one month after the booster dose.
Conclusions: Anti-SARS-CoV-2 spike RBD antibodies level at one-month post-vaccination in population who received BNT162b2 as the third dose after fully vaccinated with Sinovac were higher compared to those who received ChAdOx1 nCoV-19 as the third dose. Additional data may be necessary to fully elucidate the long-term response. (Funded by Nakornping hospital)
References
Angkasekwinai N, Sewatanon J, Niyomnaitham S, Phumiamorn S, Sukapirom K, Sapsutthipas S, et al. Safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. MedRxiv. medRxiv 2021.10.03.21264451. doi: https://doi.org/10.1101/2021.10.03.21264451
Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody status and incidence of SARS- CoV-2 infection in health care workers. N Engl J Med. 2021;384(6):533-40. doi: 10.1056/NEJMoa2034545.
Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun. 2021;12(1):1162. doi: 10.1038/s41467-021-21444-5.
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-44. doi: 10.1038/s41586-021-03207-w.
Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X.
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-92. doi: 10.1016/S1473-3099(20)30843-4.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-12. doi: 10.1016/S1473-3099(20)30987-7.
Benjamanukul S, Traiyan S, Yorsaeng R, Vichaiwattana P, Sudhinaraset N, Wanlapakorn N, et al. Safety and immunogenicity of inactivated COVID‐19 vaccine in health care workers. J Med Virol. 2022;94(4):1442-9. doi: 10.1002/jmv.27458.
Mok CKP, Cohen CA, Cheng SMS, Chen C, Kwok KO, Yiu K, et al. Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology. 2022;27(4):301-10. doi: 10.1111/resp.14191.
Yigit M, Ozkaya‐Parlakay A, Cosgun Y, Ince YE, Bulut YE, Senel E. Should a third booster dose be scheduled after two doses of CoronaVac? A single‐center experience. J Med Virol. 2022;94(1):287-90. doi: 10.1002/jmv.27318.
Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94(1):39-41. doi: 10.1002/jmv.27350.
Prasithsirikul W, Pongpirul K, Nopsopon T, Phutrakool P, Pongpirul W, Samuthpongtorn C, et al. Immunogenicity of ChAdOx1 nCoV-19 booster vaccination following two CoronaVac shots in healthcare workers. Vaccines (Basel). 2022;10(2):217. doi: 10.3390/vaccines10020217.
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91. doi: 10.1016/S0140-6736(21)00432-3.
Medians and interquartile ranges. In: Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. England: A John Wiley & Sons; 2011. Available from: https://handbook-5-1.cochrane.org/chapter_7/7_7_3_5_mediansand_interquartile_ranges.htm
Ongkittikul S, Rompho P. SARS-CoV-2 IgG antibody response after immunization of healthcare workers with inactivated COVID-19 vaccine (CoronaVac) at Phyathai 3 hospital. The Bangkok Medical Journal. 2021;17(2):100-3. [In Thai]
Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-65. doi: 10.1128/CVI.00131-10.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861-80. doi: 10.1016/j.cell.2021.01.007.
Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258-76. doi: 10.1016/S0140-6736(21)02717-3.
Sauré D, O'Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Lancet Infect Dis. 2022;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5.
Wang J, Tong Y, Li D, Li J, Li Y. The impact of age difference on the efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:758294. doi: 10.3389/fimmu.2021.758294.
Ou X, Jiang J, Lin B, Liu Q, Lin W, Chen G, et al. Antibody responses to COVID‐19 vaccination in people with obesity: A systematic review and meta‐analysis. Influenza Other Respir Viruses. 2023;17(1):e13078. doi: 10.1111/irv.13078.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nakornping Hospital
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles that had been published in the journal is copyright of Journal of Nakornping hospital, Chiang Mai.
Contents and comments in the articles in Journal of Nakornping hospital are at owner’s responsibilities that editor team may not totally agree with.
